Zobrazeno 1 - 3
of 3
pro vyhledávání: '"I. M. Biagini"'
Autor:
E. Mociran, J. Sloan-Lancaster, D. Cristei, Mark C. Genovese, I. M. Biagini, G. Mirea, S. Bojin, L. Georgescu
Publikováno v:
Arthritis & Rheumatism. 65:880-889
Objective Tabalumab, a fully human IgG4 monoclonal antibody, neutralizes soluble and membrane-bound BAFF. The aim of this study was to examine the tolerability and efficacy of tabalumab in patients with active rheumatoid arthritis receiving methotrex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e341c70445e1a22a5b84ad8c428d0c9
https://doi.org/10.1002/art.37820
https://doi.org/10.1002/art.37820
Autor:
M C, Genovese, S, Bojin, I M, Biagini, E, Mociran, D, Cristei, G, Mirea, L, Georgescu, J, Sloan-Lancaster
Publikováno v:
Arthritis and rheumatism. 65(4)
Tabalumab, a fully human IgG4 monoclonal antibody, neutralizes soluble and membrane-bound BAFF. The aim of this study was to examine the tolerability and efficacy of tabalumab in patients with active rheumatoid arthritis receiving methotrexate.In thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::20b54be7e1e87ed0989a948051269c80
https://pubmed.ncbi.nlm.nih.gov/23359344
https://pubmed.ncbi.nlm.nih.gov/23359344
Autor:
I. M. Biagini, F. Van den Bosch, S. A. Roberson, J. Sloan-Lancaster, Mark C. Genovese, Peter F J Ryan, S. Bojin
Publikováno v:
Arthritis and rheumatism. 62(4)
Objective We undertook this study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LY2439821, a humanized anti–interleukin-17 (anti–IL-17) monoclonal antibody, in a first in-human trial in rheumatoid arthritis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::002407ce66adb73864db12d27cd32152
https://pubmed.ncbi.nlm.nih.gov/20131262
https://pubmed.ncbi.nlm.nih.gov/20131262